(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.64%.
Adial Pharmaceuticals's earnings in 2026 is -$7,770,762.On average, 5 Wall Street analysts forecast ADIL's earnings for 2026 to be -$8,410,711, with the lowest ADIL earnings forecast at -$14,894,307, and the highest ADIL earnings forecast at -$2,295,818. On average, 4 Wall Street analysts forecast ADIL's earnings for 2027 to be -$3,345,335, with the lowest ADIL earnings forecast at -$5,230,864, and the highest ADIL earnings forecast at -$1,282,957.
In 2028, ADIL is forecast to generate -$3,738,904 in earnings, with the lowest earnings forecast at -$3,592,280 and the highest earnings forecast at -$3,848,872.